Vulcabras Azaleia S.A (VULC3)
Sao Paulo Exchange · Brazil · prices in BRL · close of 16 Oct 2026
Key indicators
| Last close | BRL 15.07 |
|---|---|
| 52-week range | 12.72 – 22.37 |
| Return, 1 month / 3 months | +8.0% / +5.0% |
| Return, 1 year / 3 years | −9.3% / +24.6% |
| Trend | Below its 200-day average |
| RSI (14) | 58 |
| Volatility (1 year) | 31.9% |
| Worst drawdown (1 year) | -41.1% |
| Average daily value traded | 30.21M BRL |
| Dividend yield | 21.4% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Vulcabras Azaleia is a Brazilian footwear company based in the state of Sao Paulo. It designs, makes and sells shoes for everyday wear and for sport, including athletic footwear sold under brands it owns or licenses. Its customers are mainly consumers in Brazil and other Latin American markets, who buy its products through retailers and shoe shops. The company also produces components and materials used in shoe manufacturing, and it supplies footwear for men, women and children across a range of price points.
The shares are listed on the Sao Paulo Exchange in Brazil under the code VULC3, and the price on this page is in Brazilian reais (BRL). Our dividend records, which start in 2019, show payments in 5 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Vulcabras Azaleia S.A (VULC3) trades on the Sao Paulo Exchange in Brazil. It last closed at BRL 15.07 on 16 October 2026.
Its price-based Market X-Ray is 48 out of 100 (a weak price profile), ranking 829 of 1,454 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 9.3% and over the last three months it rose 5.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Sao Paulo Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 26 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -4.2% | ||
| From 52-week high | -31.6% | ||
| Momentum | 35 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | 5.0% | ||
| 6-month return | -11.9% | ||
| 12-month return, skipping the last month | -16.1% | ||
| Stability (higher is calmer) | 50 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 31.9% | ||
| Worst drawdown, 1 year (smaller is calmer) | -41.1% | ||
| Liquidity | 93 · Strong | Trades actively. | |
| Average daily value traded | 30.21M BRL | ||
| Zero-volume days | 0.0% | ||
| Income | 62 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 21.4% | ||
| Years with dividends | 5 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | −2.5% |
|---|---|
| 1 month | +8.0% |
| 3 months | +5.0% |
| 6 months | −11.9% |
| 1 year | −9.3% |
| 3 years | +24.6% |
| 5 years | – |
Signals
| 50-day / 200-day average | 13.84 / 15.74 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.52 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 22 Dec 2025 | BRL 0.6500 |
| 15 Dec 2025 | BRL 0.1250 |
| 17 Nov 2025 | BRL 0.1250 |
| 4 Nov 2025 | BRL 2.2000 |
| 20 Oct 2025 | BRL 0.1250 |
| 17 Sep 2025 | BRL 0.1250 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Sao Paulo Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.